CTOs on the Move

Linnaeus Therapeutics

www.linnaeustx.com

 
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.linnaeustx.com
  • 30 Washington Ave Suite F
    Haddonfield, NJ USA 08033
  • Phone: 856.433.1300

Executives

Name Title Contact Details

Funding

Linnaeus Therapeutics raised $12M on 09/17/2019

Similar Companies

Molecular Express

Molecular Express is a Rancho Dominguez, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Excision BioTherapeutics

Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Med-Metrix

Med-Metrix is a leading provider of performance management analytics, consulting, extended business office, and revenue recovery services to the healthcare industry. Our firm was founded by a veteran management team with a successful track record providing superior service and technology to Hospitals.

Astellas Venture Capital

Astellas Venture Capital is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BPGbio

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.